SYNCOM FORMULATIONS (INDIA) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.8 INR | +0.15% |
|
+8.75% | -8.24% |
| Mar. 29 | Syncom Formulations Limited Announces Board Changes | CI |
| Feb. 14 | Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Sales 2022 | 2.2B 26.35M | Sales 2023 | 2.24B 26.9M | Capitalization | 5.55B 66.54M |
|---|---|---|---|---|---|
| Net income 2022 | 198M 2.38M | Net income 2023 | 201M 2.41M | EV / Sales 2022 | 4.25 x |
| Net Debt 2022 | 160M 1.92M | Net Debt 2023 | 123M 1.47M | EV / Sales 2023 | 2.53 x |
| P/E ratio 2022 |
46.9
x | P/E ratio 2023 |
27.3
x | Employees | 555 |
| Yield 2022 |
0.28% | Yield 2023 |
-
| Free-Float | 49.28% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.15% | ||
| 1 week | +8.75% | ||
| Current month | +23.43% | ||
| 1 month | +15.77% | ||
| 3 months | -9.45% | ||
| 6 months | +73.15% | ||
| Current year | -8.24% |
1 week
12.84
14.45
1 month
11.0114.45
Current year
11.0118.65
1 year
6.0418.65
3 years
4.5519.49
5 years
0.3919.49
10 years
0.3919.49
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 88-06-20 | |
| Director of Finance/CFO | - | 14-03-31 | |
Vaishali Agrawal
CMP | Compliance Officer | - | 23-05-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 71 | 88-06-20 | |
| Founder | 65 | 88-06-20 | |
| Director/Board Member | 36 | 17-11-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 13.8 | +0.15% | 458 990 |
| 24-04-25 | 13.78 | -1.85% | 429,244 |
| 24-04-24 | 14.04 | +1.23% | 1,354,982 |
| 24-04-23 | 13.87 | +5.00% | 1,177,893 |
| 24-04-22 | 13.21 | +4.92% | 483,437 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am EDT
More quotes
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.24% | 155M | |
| +26.09% | 653B | |
| +27.00% | 556B | |
| -6.61% | 354B | |
| +20.95% | 331B | |
| +2.52% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -5.90% | 144B |
- Stock Market
- Equities
- SYNCOMF Stock
